Newly Described Type of Immune Cell and T Cells Share Similar Path to Maturity
News May 15, 2013
Labs around the world, and a core group at Penn, have been studying recently described populations of immune cells called innate lymphoid cells (ILCs). Some researchers liken them to foot soldiers that protect boundary tissues such as the skin, the lining of the lung, and the lining of the gut from microbial onslaught. They also have shown they play a role in inflammatory disease, when the body’s immune system is too active.
In animal studies, group-2 innate lymphoid cells (ILC2s) confer immunity during a parasitic infection in mice and are also involved in allergic airway inflammation. A team of Perelman School of Medicine, researchers from the Departments of Medicine, Microbiology, Pathology and Laboratory Medicine, and Cancer Biology, found that maturation of ILC2s requires T-cell factor 1 (TCF-1, the product of the Tcf7 gene) to move forward. TCF-1 is protein that binds to specific parts of DNA to control transcription of genetic information from DNA to messenger RNA.
Avinash Bhandoola, PhD, professor of Pathology and Laboratory Medicine, and Qi Yang, PhD, a postdoc in the Bhandoola lab, describe in Immunity that one mechanism used to build ILCs is the same as that in T cells. Both cell types use a protein pathway centered on Notch that the lab of coauthor Warren Pear, MD, PhD, also in the Pathology and Laboratory Medicine, has studied for the last two decades. Other contributing authors are from the laboratory of David Artis, PhD in Microbiology, that are experts in ILC function, and Angela Haczku, MD, PhD, in the Department of Medicine, who focuses on asthma.
But what makes ILCs and T cells different in their final development? T cells are made in the thymus. ILCs don’t need the thymus, but researchers don’t know exactly where they are produced, just that the thymus isn’t essential for their normal development, unlike T cells.
In the Immunity study, mice without the Tcf7 gene also lack ILC2, and were unable to mount an ILC2 immune response. Forced expression of TCF-1 in bone marrow progenitor cells in the mice partially bypassed the requirement for Notch signaling in the generation of ILC2 in the mice. The researchers suggest that transcription factors such as TCF-1 that underlie early steps of T cell development are also implicated in the development of innate lymphoid cells.
The collaborators’ next steps are to better understand the basic steps of ILC development and build mouse models to test ILC function. “We want to know where ILCs develop in the body and what progenitor cells give rise to ILCs.” says Bhandoola. “If we succeed in constructing mouse models missing different types of ILC, our collaborators can use them to better figure out what these cells do, and perhaps eventually how to control them.”
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.